Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORAFENIB/BINIMETINIB Master Protocol Continuation Study (FLOTILLA)
2023-509408-13-00Phase 4Authorised
- Sponsor
- Pfizer
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 4, open-label, single-arm trial of encorafenib and binimetinib in Nonhematologic neoplasms, sponsored by Pfizer. Primary endpoints: Adverse events leading to permanent discontinuation of study intervention and Serious adverse events. Planned start Aug 2024; status: authorised.
02
Drugs
encorafenibbinimetinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-509408-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509408-13-00.